The Administrative Core provides the infrastructure for and coordinates all activities of the MPD Research Consortium (MPD-RC). Key functions include organizational management and communication, resource allocation and management (personnel, funds,equlpment, and supplies), organization of all internal and external advisory boards, scientific and clinical trials oversight to assure regulatory cornpliarice and procedural implementation, and exetmal liaison to appropriate governmental agencies.
The specific aims of the Administrative are: 1) coordinate activities of all projects, and cores belonging to the MPD-RC;2) schedule and provide optimal staff support for all MPD-RC committees and boards and establish and staff new committees when necessary;3) assure that the use of both human subjects and animal subjects is monitored in compliance with NIH regulations for research using human subjects and animals;4) administer and oversee all budgets;5) liaison to the NCI for all matters pertaining to the MPD-RC;6) submit all applications for use of Investigational New Drugs (IND) to the U.S. Federal Drug Administration;7) report all adverse events experienced by patients participating in clinical trials to investigators, participating instituions and appropriate regulatory agencies;8) develop and negotiate contracts with pharmaceutical companies to gain access to drugs to be administered in clinical trials and obtain partial support from pharmaceutical companies for the performance of these trials;9) prepare and provide yearly progress reports to the NCI.
The Administrative Core is a critical resource which coordinates the activities of the 6 projects and other cores which comprise the MPD-RC. This core provides an organizational foundation which permits the investigators who are located at multiple geographic sites across 9 time zones to closely and effectively interact.
|Wang, Xiaoli; Cho, Sool Yeon; Hu, Cing Siang et al. (2015) C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients. Exp Hematol 43:100-9.e1|
|Wehrle, Julius; Pahl, Heike L; von Bubnoff, Nikolas (2014) Ponatinib: a third-generation inhibitor for the treatment of CML. Recent Results Cancer Res 201:99-107|
|Spivak, Jerry L; Considine, Michael; Williams, Donna M et al. (2014) Two clinical phenotypes in polycythemia vera. N Engl J Med 371:808-17|
|Dickinson, Rachel E; Milne, Paul; Jardine, Laura et al. (2014) The evolution of cellular deficiency in GATA2 mutation. Blood 123:863-74|
|Rondelli, Damiano; Goldberg, Judith D; Isola, Luis et al. (2014) MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood 124:1183-91|
|Rheinemann, Lara; Seeger, Thalia S; Wehrle, Julius et al. (2014) NFE2 regulates transcription of multiple enzymes in the heme biosynthesis pathway. Haematologica 99:e208-10|
|Kapralova, Katarina; Lanikova, Lucie; Lorenzo, Felipe et al. (2014) RUNX1 and NF-E2 upregulation is not specific for MPNs, but is seen in polycythemic disorders with augmented HIF signaling. Blood 123:391-4|
|Wang, L; Swierczek, S I; Drummond, J et al. (2014) Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes. Leukemia 28:935-8|
|Ye, Zhaohui; Liu, Cyndi F; Lanikova, Lucie et al. (2014) Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells. Stem Cells 32:269-78|
|Essig, Aitomi; Duque-Afonso, Jesus; Schwemmers, Sven et al. (2014) The AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic precursor cells. Leuk Res 38:340-5|
Showing the most recent 10 out of 116 publications